Table 2 Associations of clinical variables to a patient having an hVISA infection

Age

0.541

1.0 (1.0–1.0)

Sex

0.532

1.9 (0.3–13.6)

Site of acquisition

0.008

0.5 (0.3–0.8)

Solid cancer

0.684

1.1 (0.7–1.7)

Hematological malignancy

0.176

0.4 (0.1–1.4)

Biliary disease

0.369

0.8 (0.4–1.4)

Neurological disorder

0.747

1.1 (0.6–1.9)

Diabetes mellitus

0.805

1.1 (0.7–1.6)

Hypertension

0.902

1.0 (0.6–1.5)

Alcohol use disorder

0.263

1.5 (0.7–3.3)

Chronic renal failure

0.540

0.7 (0.2–2.0)

End-stage renal disease

0.778

1.1 (0.6–2.1)

Liver cirrhosis

0.173

0.6 (0.3–1.2)

Solid organ transplantation

0.657

1.2 (0.5–2.7)

Haematopoietic stem cell transplantation

0.260

2.2 (0.6–8.7)

COPD or bronchiectasis

0.440

0.7 (0.2–1.8)

Rheumatological disease

0.338

0.6 (0.1–1.7)

Ischemic heart disease

0.692

0.9 (0.5–1.6)

Heart failure

0.245

1.7 (0.7–4.2)

Neutropenia

0.993

1.0 (0.3–3.1)

Recent surgery

0.654

1.1 (0.7–1.7)

Chemotherapy

0.384

0.7 (0.3–1.6)

Immunosuppressive therapy

0.259

1.3 (0.8–2.1)

Sepsis grade

0.640

0.9 (0.8–1.2)

Site of infection

0.254

1.0 (1.0–1.0)

Previous anti-MRSA therapy

0.006

2.0 (1.2–3.4)

Previous VAN use

0.024

1.7 (1.1–2.6)

VAN MIC by BMD

<0.001

15.2 (7.8–30.9)

Interaction: age × sex

0.865

1.0 (1.0–1.0)